Comprehensive Financial Consultants Institutional Inc. Acquires 2,091 Shares of Medtronic PLC $MDT

Comprehensive Financial Consultants Institutional Inc. grew its holdings in Medtronic PLC (NYSE:MDT) by 4.5% during the 2nd quarter, Holdings Channel reports. The firm owned 48,781 shares of the medical technology company’s stock after purchasing an additional 2,091 shares during the period. Medtronic makes up approximately 1.4% of Comprehensive Financial Consultants Institutional Inc.’s portfolio, making the stock its 18th biggest position. Comprehensive Financial Consultants Institutional Inc.’s holdings in Medtronic were worth $4,252,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. 1248 Management LLC acquired a new stake in shares of Medtronic in the 1st quarter valued at approximately $26,000. Columbia River Financial Group LLC acquired a new stake in shares of Medtronic in the 1st quarter valued at approximately $28,000. Twin Tree Management LP acquired a new stake in shares of Medtronic in the 1st quarter valued at approximately $29,000. Activest Wealth Management raised its position in shares of Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares during the period. Finally, Hughes Financial Services LLC acquired a new stake in shares of Medtronic in the 1st quarter valued at approximately $32,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

Shares of MDT stock opened at $97.63 on Monday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. The company has a market capitalization of $125.23 billion, a P/E ratio of 26.90, a price-to-earnings-growth ratio of 2.57 and a beta of 0.78. The company’s 50 day moving average price is $92.94 and its two-hundred day moving average price is $88.46. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $97.94.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same period last year, the company posted $1.23 EPS. The business’s quarterly revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be issued a $0.71 dividend. The ex-dividend date is Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is 78.24%.

Insider Buying and Selling

In other news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William R. Jellison acquired 2,500 shares of the stock in a transaction dated Monday, August 25th. The stock was acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the acquisition, the director directly owned 5,000 shares of the company’s stock, valued at $461,850. The trade was a 100.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.26% of the stock is owned by company insiders.

Analyst Ratings Changes

MDT has been the topic of a number of analyst reports. Sanford C. Bernstein increased their price target on shares of Medtronic from $97.00 to $98.00 and gave the company an “outperform” rating in a research report on Wednesday, August 20th. Leerink Partners initiated coverage on shares of Medtronic in a research report on Monday, June 16th. They issued an “outperform” rating and a $110.00 price target on the stock. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a research report on Saturday, September 27th. The Goldman Sachs Group cut their price target on shares of Medtronic from $82.00 to $81.00 and set a “sell” rating on the stock in a research report on Wednesday, October 1st. Finally, Daiwa Capital Markets raised their target price on shares of Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, September 12th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $100.94.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.